Merck KGaA reported a 16.6% decline in contract manufacturing due to an unrepeated Covid-19 contract, though overall life ...

After a research note raised potential safety concerns with Amgen's lead obesity candidate, the company defended its drug and ...

Merck & Co. has struck a licensing deal with LaNova Medicines that is potentially worth more than $3 billion to the clinical-stage biotechnology company.

In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from ...

Merck & Co. is paying $588 million upfront to defend its Keytruda kingdom. The outlay, plus up to $2.7 billion in milestones, ...

Driven by growth across the board, including in its semiconductor business, German science and technology company Merck ...

The German life-science and chemicals company attributed earnings growth to a recovery of its life-science segment, cost discipline and lower spending on research and development following the ...

(Bloomberg) -- Merck KGaA posted earnings that topped estimates as its life science unit recovers from its post-pandemic ...

FRANKFURT, Nov 14 (Reuters) - Merck KGaA (MRCG.DE), opens new tab on Thursday reported ... compared with 5.9 billion reported ...

Most recently, he served as Chief Operating Officer of Prometheus Biosciences, a biotechnology company focused on gastrointestinal diseases that was acquired by Merck for $10.8 billion ... leadership ...

Multiple sclerosis (MS) is a chronic neurological disorder affecting the central nervous system (CNS), particularly the brain, spinal cord, and optic nerves. Continuous research has led to new drug ...

Through its Life Science Solutions segment, the firm operates in the genomics market. The company has a strong geographic presence across more than 100 countries. The company offers genomics products ...